Mostrando 1,281 - 1,300 Resultados de 7,829 Para Buscar '"LP"', tiempo de consulta: 0.38s Limitar resultados
  1. 1281
    “…Compared to SP patients, differences in passing trial void (LP 94.44%, SP 93.45%), postoperative UTI (LP 19.44%, SP 10.12%), ED visits (LP 22.22%, SP 17.86%), readmissions (LP 8.33%, SP 4.76%), and retreatment (LP 8.33%, SP 4.76%) were insignificant. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
  2. 1282
  3. 1283
    “…The building was highly colonized with Lp with 71% Lp positivity. Single HS had a statistically significant Lp reduction one day post treatment but no significant Lp reduction one, two, and four weeks post treatment. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
  4. 1284
    “…Lipoprotein(a) (Lp[a]) is a particle consisting of a low‐density lipoprotein (LDL)‐like core connected to an apolipoprotein(a) chain, which is an established risk factor for cardiovascular disease. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
  5. 1285
  6. 1286
    “…Male Institute of Cancer Research (ICR) strain mice were divided into three groups (n = 8 per group) for oral administration of LP10 for six weeks at 0, 2.05 × 10(8), or 1.03 × 10(9) colony-forming units/kg/day, designated the vehicle, LP10-1X and LP10-5X groups, respectively. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
  7. 1287
    por Kotani, Kazuhiko
    Publicado 2016
    “…The circulating levels of lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) can be a simple, but practical and useful marker of cardiovascular disease (CVD). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
  8. 1288
    “…In vivo pharmacokinetics demonstrated that the CA-LP–DOX/SLB-treated group showed higher liver accumulation and lower heart accumulation of DOX relative to those in the CA-LP–DOX and LP–DOX-treated groups. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
  9. 1289
    “…In immunosuppressed hosts, Legionella pneumophila (Lp) infection usually develops into severe pneumonia, which is pathologically characterized by increased vascular permeability and pulmonary edema. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
  10. 1290
    “…Lactase persistence (LP) is a well-studied example of a Mendelian trait under selection in some human groups due to gene-culture coevolution. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
  11. 1291
  12. 1292
  13. 1293
    “…Objective Lumbar puncture (LP) is a diagnostic procedure that accesses the spinal subarachnoid space to measure the opening pressure of the cerebrospinal fluid (CSF) and obtain samples of CSF for analysis. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
  14. 1294
  15. 1295
    “…Methods: 3′ and 5′ UTR variants documented as P or LP (P/LP) were obtained from ClinVar and refined by reviewing the annotated variant effect and reassessing evidence of pathogenicity following published guidelines. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
  16. 1296
    Publicado 2010
    “…BACKGROUND: Lipoprotein-associated phospholipase A(2) (Lp-PLA(2)), an inflammatory enzyme expressed in atherosclerotic plaques, is a therapeutic target being assessed in trials of vascular disease prevention. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Texto
  17. 1297
  18. 1298
    por Garg, Seema, Madhu, S.V., Suneja, Shilpa
    Publicado 2015
    “…BACKGROUND & OBJECTIVES: Lipoprotein associated phospholipase A(2) (Lp-PLA(2)) is an important risk predictor of coronary artery disease (CAD). …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
  19. 1299
  20. 1300
    “…HER2-Positive tumor cells can escape targeted therapies like LP effects by overexpressing c-Met. Combined OC-LP treatment is hypothesized to be mechanistically synergistic against HER2-overexpressing breast cancer. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
Herramientas de búsqueda: RSS